-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Schizophrenia can lead to thought and mood disorders, delusions and hallucinations, and is one of the most debilitating and mysterious mental disorders
The nature of the changes in the brain circuits of patients with schizophrenia is not yet clear-is it over-excited or not enough, over-inhibited or not enough, or some combination? In order to find the answer, the research team led by Dr.
Dr.
John Krystal, MD, editor of Biopsychiatry, said: "The study of the basic characteristics of synaptic dysfunction in schizophrenia may help guide pharmacology and neurostimulation therapies for the treatment of this disease
"Computational modeling of EEG and fMRI paradigms indicates a consistent loss of pyramidal cell synaptic gain in schizophrenia," by Rick Adams, Dimitris Pinotsis, Konstantinos Tsirlis, Leonhardt Unruh, Aashna Mahajan, Ana Montero Horas, Laura Convertino, Ann Summerfelt, Hemalatha Sampath, Hemalatha Xiaoming Michael Du, Peter Kochunov, Jie Lisa Ji, Grega Repovs, John Murray, Karl Friston, Eilliot Hong, Alan Anticevic ( https://doi.